First Longevity announces first investors for current round

Latest articles

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

Click the globe for translations.

Some news of our own: European VC fund and a Longevity innovator participate in the First Longevity funding round.

Last week we announced that Tom Britton joined our Advisory Panel as plans for our Longevity equity funding platform take another step forward. Today we’re pleased to announce a six-figure investment in our current funding round for First Longevity. We are now putting our new investors’ cash to work whilst still keeping our funding round open; enabling us to get on with our plans as this sector is growing fast – and we don’t like to drag our heels!

Among those participating in this first stage are Chairman, George Sutherland and Longevitytech.fund a new European Longevity-focused fund based in the Czech Republic. Petr Sramek (pictured), Co-founder, Chairman and Managing Partner of Longevitytech.fund, commented: “Success is a function of perfect timing, strategic position, and the team. These are exactly the ingredients we like about the First Longevity business plan.”


 

“There is exceptional progress in the science of understanding aging and at the same time it is also probably the world’s greatest and most ethical investment opportunity.”

 


 

Longevitytech.fund has already invested in another UK business, Agecurve, and with more investors entering the Longevity sector, we were interested in understanding the indicators that Petr is experiencing to demonstrate growth of the Longevity market, he told us: “There is exceptional progress in the science of understanding aging and at the same time it is also probably the world’s greatest and most ethical investment opportunity.”

George Sutherland, Chairman of First Longevity Ltd, commented: “It’s great to have Petr and his fund as an early investor and together with myself and another key investor who’s well-known in the Longevity field, we are making important steps forward while we continue with the round. While we do have commitment from other key Longevity investors, we would welcome the opportunity to chat with others who may be interested in the round.

First Longevity Ltd has been formed to capitalise on the growing Longevity opportunity. This news platform launched in September 2019 and delivers daily news and insights to a growing international audience of investors, start-ups, academics and consumers. The next stage of our plan is a digital equity fundraising platform, Crowd Longevity, which will present pre-screened Longevity tech businesses to our growing investor community.

We recently announced the appointment of our Advisory Panel of leading experts from Longevity science and investment: the Board and the Advisory Panel will support the development of unique media content while reviewing the scientific, technical and investment potential of companies presented to equity investors.

Thanks to you for your ongoing interest and advocacy!

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Sugar-proof your health with the GLYLO weight loss and antiaging supplement

Move your New Year's resolution up a gear with GLYLO, a double-action supplement that can increase weight loss while also slowing aging. Choosing an effective...

Related articles

Cellino bags $80 million to autonomise stem cell therapy manufacturing

Leaps by Bayer leads $80m Series A to enable Cellino to significantly expand patient access to stem cell-based therapies. Cellino Biotech, Inc, an autonomous stem cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Mental illness drug discovery company Neurai Life Sciences launches

AI will drive discovery of innovative small molecules and next generation therapies to treat mental health disorders. Wuhan, a bioceutical company focused on alternative plant-based...

Altos Labs lands $3 billion to further cellular rejuvenation programming

Altos Labs launches with the goal to transform medicine through cellular rejuvenation programming. Altos Labs launched today as a new biotechnology company dedicated to unravelling...

StarkAge secures 2 million euros for senescence targeting therapy

Funding from Bpifrance's Deeptech program will drive development of company’s immunotherapy approach targeting cellular senescence in age-related disease. French biotech startup StarkAge Therapeutics today announced...

    Subscribe to our newsletter